Ventripoint Extends Patent Portfolio with Foundational U.S. Provisional Patent Filing of Heart Motion Tracking Technology

Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company“), (TSXV:VPT) (OTC:VPTDF) has filed a U.S. provisional patent application for its novel cardiac measurement approach.

This new measurement technique provides cardiologists with additional and more precise information about the function of the heart through motion tracking.  This invention is as an extension of the Company’s existing artificial intelligence (AI) platform, which provides accurate and reliable volumetric measurements for all four chambers of the heart.  

“Since Ventripoint’s VMS+3.0 system produces a mathematical model of the entire heart throughout the cardiac cycle, we are able to create novel measurements to characterize the function of the whole heart.  This is now becoming even more important with the myriad of effects of COVID-19 on the heart,” stated Dr. George Adams, Executive-Chairman of Ventripoint.      

This new technology tracks the movement of heart and valves through the entire heartbeat and not just at the full and empty points in the cardiac cycle.  This dynamic information can help in initial diagnosis and assessing the effectiveness of treatments, as well as the timing of interventions thereby improving clinical outcomes.

Cardiovascular diseases continue to be the number 1 cause of death worldwide. Constantly advancing the tools available to clinicians for treating and diagnosing patients is key for the future of healthcare.

For more information on the Ventripoint products, please refer to the Ventripoint website:

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint’s VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint’s products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Mr. Jonathan Robinson


Phone: (416) 669-1001‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬


Mr. Anthony Allocca


Phone: 858-456-7300

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company’s most recent annual management’s discussion and analysis that is available on the Company’s profile on SEDAR at Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.